Artículos por temáticas

The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease

Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G.

Nutr Res. 2016 Dec;36(12):1305-1315. doi: 10.1016/j.nutres.2016.11.002. Epub 2016 Nov 8.

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients

Mizokami F, Takahashi Y, Hasegawa K, Hattori H, Nishihara K, Endo H, Furuta K, Isogai Z.

J Dermatol. 2016 Apr;43(4):436-8. doi: 10.1111/1346-8138.13093. Epub 2015 Sep 14.

Phage M13 for the treatment of Alzheimer and Parkinson disease

Messing J.

Gene. 2016 Jun 1;583(2):85-89. doi: 10.1016/j.gene.2016.02.005. Epub 2016 Feb 8.

[Immunotherapy is a possible treatment for future Alzheimer’s disease patients]

Lolk A.

Ugeskr Laeger. 2016 Jun 13;178(24):V68110.

[Research progress in pharmacological effects of Uncaria Hook on Alzheimer disease models]

Liu L, Zhao YH, Zeng CQ, Zeng Y.

Yao Xue Xue Bao. 2016 Apr;51(4):536-42.

Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings

Heßmann P, Seeberg G, Reese JP, Dams J, Baum E, Müller MJ, Dodel R, Balzer-Geldsetzer M.

J Alzheimers Dis. 2016;51(2):545-61. doi: 10.3233/JAD-150835.

[Internal consistency and construct validity of the Quality of Life in Alzheimer's Disease (QoL-AD) proxy – a secondary data analysis]

Hylla J, Schwab CG, Isfort M, Halek M, Dichter MN.

Pflege. 2016 Jul;29(4):183-91. doi: 10.1024/1012-5302/a000494. Epub 2016 May 30.

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study

Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porstei

Am J Psychiatry. 2016 May 1;173(5):473-80. doi: 10.1176/appi.ajp.2016.15020248. Epub 2016 Apr 1.

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.

Alzheimers Res Ther. 2016 Jun 30;8:25. doi: 10.1186/s13195-016-0194-x.

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device

Eyjolfsdottir H, Eriksdotter M, Linderoth B, Lind G, Juliusson B, Kusk P, Almkvist O, Andreasen N, Blennow K, Ferreira D, Westman E, Nennesmo I, Karami A, Darreh-Shori T, Kadir A, Nordberg A, Sundströ

Alzheimers Res Ther. 2016 Jul 7;8(1):30. doi: 10.1186/s13195-016-0195-9.

Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress

Ali MR, Abo-Youssef AM, Messiha BA, Khattab MM.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Jun;389(6):637-56. doi: 10.1007/s00210-016-1234-6. Epub 2016 Mar 30.

Factors Associated With Preferences for Institutionalized Care in Elderly Persons: Comparing Hypothetical Conditions of Permanent Disability and Alzheimer's Disease

Werner P, Segel-Karpas D.

J Appl Gerontol. 2016 Apr;35(4):444-64. doi: 10.1177/0733464814546041. Epub 2014 Sep 22.

Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway

Zhao L, Zhao Q, Zhou Y, Zhao Y, Wan Q.

CNS Neurol Disord Drug Targets. 2016;15(1):80-5. doi: 10.2174/1871527315999160111160143.

Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial

Beauchet O, Barden J, Liu-Ambrose T, Chester VL, Annweiler C, Szturm T, Grenier S, Léonard G, Bherer L, Allali G; Canadian Gait Consortium.

Drugs Aging. 2016 Sep;33(9):665-73. doi: 10.1007/s40266-016-0391-0.